发布求助
文献互助 智能选刊 最新文献

The Lancet. Oncology最新文献

筛选
英文 中文
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer? 米托坦：卡博替尼治疗肾上腺皮质癌前的 "敌 "还是 "友"？
The Lancet. Oncology Pub Date : 2024-04-01 DOI: 10.1016/s1470-2045(24)00151-7
M. Wierman
{"title":"Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?","authors":"M. Wierman","doi":"10.1016/s1470-2045(24)00151-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00151-7","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":"45 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Oncol 2022; 23: e480. Lancet Oncol 2022更正;23: e480。
IF 51.1
The Lancet. Oncology Pub Date : 2022-12-01 DOI: 10.1016/S1470-2045(22)00708-2
{"title":"Correction to Lancet Oncol 2022; 23: e480.","authors":"","doi":"10.1016/S1470-2045(22)00708-2","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00708-2","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e531"},"PeriodicalIF":51.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40458450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thoracic CT follow-up after non-small-cell lung cancer resection. 非小细胞肺癌切除术后胸部CT随访。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00618-0
Gavitt A Woodard, Daniel J Boffa, Justin D Blasberg
{"title":"Thoracic CT follow-up after non-small-cell lung cancer resection.","authors":"Gavitt A Woodard, Daniel J Boffa, Justin D Blasberg","doi":"10.1016/S1470-2045(22)00618-0","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00618-0","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e484"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40663522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accelerating the integration of China into the global development of innovative anticancer drugs. 加快中国创新抗癌药物融入全球发展。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00483-1
Huiyao Huang, Dawei Wu, Huilei Miao, Yu Tang, Chengcheng Liu, Hong Fang, Xinyu Meng, Shuhang Wang, Qi Zhu, Xin Wang, Jingting Du, Zhimin Yang, Ning Li, Binghe Xu, Jie He
{"title":"Accelerating the integration of China into the global development of innovative anticancer drugs.","authors":"Huiyao Huang,&nbsp;Dawei Wu,&nbsp;Huilei Miao,&nbsp;Yu Tang,&nbsp;Chengcheng Liu,&nbsp;Hong Fang,&nbsp;Xinyu Meng,&nbsp;Shuhang Wang,&nbsp;Qi Zhu,&nbsp;Xin Wang,&nbsp;Jingting Du,&nbsp;Zhimin Yang,&nbsp;Ning Li,&nbsp;Binghe Xu,&nbsp;Jie He","doi":"10.1016/S1470-2045(22)00483-1","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00483-1","url":null,"abstract":"<p><p>The aim of this Policy Review was to compare China's overall and synchronous participation in clinical trials for innovative anticancer drugs with that of the USA, the EU, Japan, and South Korea, and to assess changes in the participation rate trends in these five regions. Relevant data from the top 20 international pharmaceutical companies from 2011 to 2021 were systematically collected from the Trialtrove and Pharmaprojects databases. Among the 8260 trials for 954 new anticancer drugs identified, China was involved in 8·8% of the trials and with 20·4% of the drugs being trialled. These participation rates are significantly lower than those for South Korea (14·5% of trials and 36·3% of drugs), Japan (16·1% of trials and 38·7% of drugs), the EU (40·6% of trials and 67·7% of drugs), and the USA (65·7% of trials and 91·2% of drugs; p&lt;0·0001 for all). Similar results were found for the synchronous participation rate, defined as the proportion of drugs or trials at the highest development stage internationally, for the 803 tested drugs, which ranged from 9·0% in China to 87·7% in the USA. China's participation rate in early phase trials (4·4%) and in synchronous trials (5·4%) was even lower, in stark contrast to that of the USA (66·1% for early phase trials and 89·1% for synchronous trials). The fastest growing annual rate of participation in trials was observed in China (15·7%), followed by South Korea (8·2%) and Japan (6·8%); no change was detected in the USA or the EU. This Policy Review shows that Chinese participation in the clinical development of innovative cancer drugs by international pharmaceutical companies has increased over the past decade, but an obvious gap persists in comparison with the USA, the EU, Japan, and South Korea, especially in its synchronous participation and early participation rates.</p>","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e515-e520"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40664440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Increase in vaping and e-cigarette use by children in Malaysia. 马来西亚儿童使用电子烟和电子烟的人数增加。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 Epub Date: 2022-09-23 DOI: 10.1016/S1470-2045(22)00596-4
Manjulika Das
{"title":"Increase in vaping and e-cigarette use by children in Malaysia.","authors":"Manjulika Das","doi":"10.1016/S1470-2045(22)00596-4","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00596-4","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"1360"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40376425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limitations of the radiosensitivity index as a direct prognostic marker. 放射敏感性指数作为直接预后指标的局限性。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00553-8
David Robert Grimes
{"title":"Limitations of the radiosensitivity index as a direct prognostic marker.","authors":"David Robert Grimes","doi":"10.1016/S1470-2045(22)00553-8","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00553-8","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"1352-1353"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40663517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thoracic CT follow-up after non-small-cell lung cancer resection. 非小细胞肺癌切除术后胸部CT随访。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00565-4
Marjolein A Heuvelmans, Matthijs Oudkerk
{"title":"Thoracic CT follow-up after non-small-cell lung cancer resection.","authors":"Marjolein A Heuvelmans,&nbsp;Matthijs Oudkerk","doi":"10.1016/S1470-2045(22)00565-4","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00565-4","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e483"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40663521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic epithelioid aortic angiosarcoma. 转移性上皮样主动脉血管肉瘤。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00489-2
Wiaam Elkhatib, Razvan Chirila
{"title":"Metastatic epithelioid aortic angiosarcoma.","authors":"Wiaam Elkhatib,&nbsp;Razvan Chirila","doi":"10.1016/S1470-2045(22)00489-2","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00489-2","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e521"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40664441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Symptomatic melanoma CNS metastases in the TRICOTEL study. TRICOTEL研究中症状性黑色素瘤中枢神经系统转移。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00566-6
Andreas M Schmitt, James Larkin
{"title":"Symptomatic melanoma CNS metastases in the TRICOTEL study.","authors":"Andreas M Schmitt,&nbsp;James Larkin","doi":"10.1016/S1470-2045(22)00566-6","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00566-6","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e481"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40663519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Correction to Lancet Oncol 2022; 23: e469-78. Lancet Oncol 2022更正;23: e469 - 78。
IF 51.1
The Lancet. Oncology Pub Date : 2022-11-01 DOI: 10.1016/S1470-2045(22)00609-X
{"title":"Correction to Lancet Oncol 2022; 23: e469-78.","authors":"","doi":"10.1016/S1470-2045(22)00609-X","DOIUrl":"https://doi.org/10.1016/S1470-2045(22)00609-X","url":null,"abstract":"","PeriodicalId":519533,"journal":{"name":"The Lancet. Oncology","volume":" ","pages":"e492"},"PeriodicalIF":51.1,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40664436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信